High Potency FAQs
Frequently Asked Questions
Highly Potent Active Pharmaceutical Ingredients (HPAPIs) are compounds with very low Occupational Exposure Limits
(OELs), often below 1 μg/m³. Their potency requires specialized containment, engineering controls, and safety systems
to protect operators, the environment, and product integrity.
HPAPIs are banded into Occupational Exposure Bands (OEBs) based on OEL values, typically ranging from OEB1 (>100
μg/m³) to OEB5 (<0.1 μg/m). This classification drives containment strategy, facility design, and operational controls.
Key factors include:
- Proven HPAPI expertise and safety systems
- Robust potency and toxicity assessment capabilities
- State-of-the-art engineering and containment controls
- Strong cleaning validation and quality systems
- Integrated R&D, analytical, and manufacturing services
- Organizational commitment to HPAPI excellence
Hazard assessment incorporates toxicity data, structural analogs, mode of action, intermediates and raw materials,
thermal stability, dust and explosivity testing, gas flow dynamics, and electrostatic discharge risk.
Personal Protective Equipment (PPE) is considered the last line of defense. Effective HPAPI manufacturing relies
primarily on engineering controls, such as HVAC systems, pressure gradients, and closed handling, to prevent exposure
at the source.
Controls include independent HVAC systems, pressure cascades, closed material transfers, no open powder handling,
full treatment or capture of process streams, and emergency backup systems for critical utilities.
Controlled personnel flow, dedicated material pathways, and cascading room pressurization gradients minimize the
risk of cross-contamination and uncontrolled exposure during manufacturing operations.
Common technologies include rigid barrier isolators, soft-sided or disposable containment systems, split-butterfly
valves, continuous liner systems, rapid transfer ports, and specialized milling and filtration equipment.
Single-use systems can provide very low containment limits, rapid turnaround for clinical programs, reduced
cross-contamination risk, elimination of cleaning validation, and less dependence on dedicated equipment.
Cleaning approaches are selected using a risk-based matrix considering OEB, solubility, and acceptable surface
limits. Strategies may include single-use components, dedicated equipment, and advanced analytical verification
such as TOC testing.
Cross-contamination is managed through industrial hygiene calculations, defined NOEL-based cleaning limits,
highly sensitive analytical methods, and validated cleaning verification protocols.
HPAPI manufacturing requires organization-wide dedication, specialized training, certified competency programs,
regulatory success, and a strong safety culture. Corporate commitment ensures consistent execution across all
stages and sites.
HPAPIs commonly include oncology agents, hormones, steroids, antibody-drug conjugate payloads, and other
small molecules with high biological activity.
The right partner acts as a dedicated ally—reducing risk, accelerating timelines, ensuring compliance, and
supporting the product from early development through commercial supply.
